Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 440

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression

Zhang, Hao, Wei, Jing, Xue, Rong, Wu, Jin-Dan, Zhao, Wei, Wang, Zi-Zheng, Wang, Shu-Kui, Zhou, Zheng-Xian, Song, Dan-Qing, Wang, Yue-Ming, Pan, Huai-Ning, Kong, Wei-Jia, Jiang, Jian-Dong·2010·Metabolism
DOI 10.1016/j.metabol.2009.07.029
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.metabol.2009.07.029

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 35

  1. Saltiel, 2001, New perspectives into the molecular pathogenesis and treatment of type 2 diabetes, Cell, 104, 517, 10.1016/S0092-8674(01)00239-2 · DOI · Paper page
  2. Kido, 2001, Clinical review 125: the insulin receptor and its cellular targets, J Clin Endocrinol Metab, 86, 972
  3. Michael, 2000, Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction, Mol Cell, 6, 87, 10.1016/S1097-2765(05)00015-8 · DOI · Paper page
  4. Yki-Jarvinen, 1994, Pathogenesis of non–insulin-dependent diabetes mellitus, Lancet, 343, 91, 10.1016/S0140-6736(94)90821-4 · DOI · Paper page
  5. Haffner, 1999, Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study, Diabetes Care, 22, 562, 10.2337/diacare.22.4.562 · DOI · Paper page
  6. Zhang, 1999, Discovery of a small molecule insulin mimetic with antidiabetic activity in mice, Science, 284, 974, 10.1126/science.284.5416.974 · DOI · Paper page
  7. Foti, 2005, Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice, Nat Med, 11, 765, 10.1038/nm1254 · DOI · Paper page
  8. Air, 2002, Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity, Nat Med, 8, 179, 10.1038/nm0202-179 · DOI · Paper page
  9. Srivastava, 2005, Insulin-mimetic and anti-diabetic effects of vanadium compounds, Diabet Med, 22, 2, 10.1111/j.1464-5491.2004.01381.x · DOI · Paper page
  10. Masubuchi, 2006, Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review, Drug Metab Pharmacokinet, 21, 347, 10.2133/dmpk.21.347 · DOI
  11. Luo, 1955, Experience of berberine in the treatment of diarrhea, Chin J Med, 41, 452
  12. Lau, 2001, Cardiovascular actions of berberine, Cardiovasc Drug Rev, 19, 234, 10.1111/j.1527-3466.2001.tb00068.x · DOI · Paper page
  13. Taylor, 1989, Control of diarrheal diseases, Annu Rev Public Health, 10, 221, 10.1146/annurev.pu.10.050189.001253 · DOI
  14. Kong, 2006, Human low-density lipoprotein receptor gene and its regulation, J Mol Med, 84, 29, 10.1007/s00109-005-0717-6 · DOI
  15. Kong, 2008, Combination of simvastatin with berberine improves the lipid-lowering efficacy, Metabolism, 57, 1029, 10.1016/j.metabol.2008.01.037 · DOI · Paper page
  16. Yang, 2008, Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators, Bioorg Med Chem Lett, 18, 4675, 10.1016/j.bmcl.2008.07.005 · DOI
  17. Abidi, 2005, Extracellular signal-regulated kinase–dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine, Arterioscler Thromb Vasc Biol, 25, 2170, 10.1161/01.ATV.0000181761.16341.2b · DOI · Paper page
  18. Kong, 2009, Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression, Metabolism, 58, 109, 10.1016/j.metabol.2008.08.013 · DOI · Paper page
  19. Ni, 1988, Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research, Zhong Xi Yi Jie He Za Zhi, 8, 711
  20. Zhao, 2008, Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis, Biomed Pharmacother, 62, 730, 10.1016/j.biopha.2008.01.007 · DOI
  21. Stumvoll, 2005, Type 2 diabetes: principles of pathogenesis and therapy, Lancet, 365, 1333, 10.1016/S0140-6736(05)61032-X · DOI · Paper page
  22. Hone, 1994, Homozygosity for a new mutation (Ile119–>Met) in the insulin receptor gene in five sibs with familial insulin resistance, J Med Genet, 31, 715, 10.1136/jmg.31.9.715 · DOI
  23. Foti, 2003, A nucleoprotein complex containing Sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene transcription, Mol Cell Biol, 23, 2720, 10.1128/MCB.23.8.2720-2732.2003 · DOI
  24. Lee, 1994, The insulin receptor: structure, function, and signaling, Am J Physiol, 266, C319, 10.1152/ajpcell.1994.266.2.C319 · DOI · Paper page
  25. Ko, 2005, Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma, Biol Pharm Bull, 28, 1431, 10.1248/bpb.28.1431 · DOI · Paper page
  26. Manley, 2003, Haemoglobin A1c—a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS), Clin Chem Lab Med, 41, 1182, 10.1515/CCLM.2003.182 · DOI
  27. Vasudevan, 2004, Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability, Diabetes Technol Ther, 6, 850, 10.1089/dia.2004.6.850 · DOI
  28. Klip, 1990, Cellular mechanism of action of metformin, Diabetes Care, 13, 696, 10.2337/diacare.13.6.696 · DOI · Paper page
  29. Liu, 2008, Effects of berberine on cell proliferation, peroxisome proliferation activated receptor gamma, CAAT/enhancer binding protein mRNA and protein expression in 3T3-L1 pre-adipocytes, Zhongguo Zhong Xi Yi Jie He Za Zhi, 28, 1005
  30. Zhou, 2008, Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats, Biol Pharm Bull, 31, 1169, 10.1248/bpb.31.1169 · DOI
  31. Huang, 2006, Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway, Biochem Biophys Res Commun, 348, 571, 10.1016/j.bbrc.2006.07.095 · DOI · Paper page
  32. Lee, 2006, Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states, Diabetes, 55, 2256, 10.2337/db06-0006 · DOI · Paper page
  33. Emslie-Smith, 2001, Contraindications to metformin therapy in patients with type 2 diabetes—a population-based study of adherence to prescribing guidelines, Diabet Med, 18, 483, 10.1046/j.1464-5491.2001.00509.x · DOI · Paper page
  34. Wagstaff, 2002, Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus, Drugs, 62, 1805, 10.2165/00003495-200262120-00007 · DOI · Paper page
  35. Rao, 2004, Impaired glucose tolerance and impaired fasting glucose, Am Fam Physician, 69, 1961

Cited by

See all 440

Metadata

Authors
Zhang, H., Wei, J., Xue, R., Wu, J.-D., Zhao, W., Wang, Z.-Z., Wang, S.-K., Zhou, Z.-X., Song, D.-Q., Wang, Y.-M., Pan, H.-N., Kong, W.-J., & Jiang, J.-D.
Venue
Metabolism
Publisher
Elsevier BV
Published
2010-02
Volume
59
Issue
2
Pages
285-292
ISSN
0026-0495 (ISSN-L)
DOI
10.1016/j.metabol.2009.07.029
OpenAlex
W2009141930
Cited by
440
References
6
FWCI
12.38
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. https://app.cochat.ai/papers/10.1016/j.metabol.2009.07.029
The paper
Zhang, H., Wei, J., Xue, R., Wu, J.-D., Zhao, W., Wang, Z.-Z., Wang, S.-K., Zhou, Z.-X., Song, D.-Q., Wang, Y.-M., Pan, H.-N., Kong, W.-J., & Jiang, J.-D. (2010). Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. https://doi.org/10.1016/j.metabol.2009.07.029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.